How Immuno-Oncology Contributes to the Fight Against Covid-19
As the Covid-19 pandemic sweeps the world, cancer research is proving a valuable resource for…
As the Covid-19 pandemic sweeps the world, cancer research is proving a valuable resource for…
French companies OSE Immunotherapeutics and MAbSilico are teaming up to drive the discovery of new…
The biotech industry has often been criticized for its lack of gender diversity. While there…
The French company OSE Immunotherapeutics has signed a partnership to use artificial intelligence to develop…
OSE Immunotherapeutics could receive up to €1.1Bn from its new partner Boehringer Ingelheim, which has…
Today, March 8, is international women's day. To celebrate the achievements of women we're revisiting…
OSE Immunotherapeutics has halted the accrual of patients in its Phase III study for Tedopi,…
OSE Immunotherapeutics has successfully completed the necessary milestones to bring a treatment for autoimmune disease…
OSE Immunotherapeutics has teamed up with Selexis in a new license agreement to support the…
Servier is offering OSE Immunotherapeutics up to €272M to get hold of an antibody therapy for…
Despite the deflating attitudes towards immuno-oncology, OSE Immunotherapeutics is forging ahead. We caught up with…
This week, we head up full speed from Geneva with our eyes aiming towards Paris. Known…